CRDL - Cardiol Therapeutics Market Capitalization-to-Revenue Ratio

Symbol and logo of brand Cardiol Therapeutics (CRDL)

Cardiol Therapeutics (CRDL) focuses on a narrow segment of anti-inflammatory agents, mitigating binary risks through orphan statuses. Final-stage trials of the CardiolRx drug are driving growth. The company's normalized P/S confirms this trend, with the value holding at 970.10. However, financial stability remains questionable, as cash flows depend on the outcomes of cannabidiol clinical tests.

CRDL - Cardiol Therapeutics Inc P/S Multiple over the range 07/17/2022 - 08/13/2022

Metric breakdowns and analytics for Cardiol Therapeutics (CRDL)

- current price and projected stock value:
Price Chart cardiolrx.com|CRDL - Consensus Target
- market capitalization statistics:
Market Value Cardiol|CRDL - Real Price to Acquire Entire Company
- book capitalization indicators:
Book Price of a Share Cardiol Therapeutics|CRDL - Book Capitalization|Market Value to Book Value cardiolrx.com|CRDL - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital Cardiol Therapeutics|CRDL - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital cardiolrx.com|CRDL - Company Aggregate Debts|Debts to Book Capitalization Cardiol|CRDL - Company Long-Term Debt|Current Liabilities Cardiol Therapeutics|Immediate Liquidity cardiolrx.com
- earnings and market ratios statistics:
CRDL - Net Income|Projected Future Earnings Cardiol Therapeutics|CRDL - Price to Earnings Ratio|Market Cap to Future Earnings Ratio cardiolrx.com|CRDL - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Cardiol|CRDL - Operating profit EBITDA|Net earnings per share for the last 12 months Cardiol Therapeutics|CRDL - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months cardiolrx.com|CRDL - Earnings growth in current year|Expected earnings per share growth for next year Cardiol Therapeutics
- issuer revenue and sales details:
CRDL - Company Revenue|Company Future Revenue cardiolrx.com|CRDL - P/S Multiple|Market Cap to Projected Revenue Cardiol
General company analysis:CRDL Cardiol Therapeutics Inc
Mass-produced product of Cardiol Therapeutics Inc.

Cardiol Therapeutics (CRDL) focuses on developing cardiology molecules without establishing large-scale production facilities. The P/S multiple relates the company's market capitalization to its annual sales volume, determining the cost per unit of revenue. Investors analyze this ratio to identify whether an asset is overheated or showing signs of financial decline. P/S fluctuation trends allow for the timely identification of an entry point, avoiding the purchase of overvalued shares at their peak.

Competitors of Cardiol Therapeutics

Price-to-Revenue Ratio REGN (regeneron.com)|iRhythm - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio LNTH|MLYS: Market Cap to Revenue|Heartflow Inc - Market Cap to Sales Volume|KMTS: P/S Multiple|esperion.com - Market Capitalization-to-Revenue Ratio|AMRN (Amarin) - P/S Multiple|Price to Sales Anteris Technologies Ltd AVR|Price-to-Revenue Ratio Tenaya Therapeutics (TNYA)|CVRX (CVRx Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple MIST (Milestone Pharmaceuticals)|P/S Multiple heartbeam.com BEAT|TENX - Price-to-Revenue Ratio|Price-to-Sales Ratio ADGM|BCDA: P/S Multiple|Price to Sales Catheter Precision Corporation (VTAK)|Market Cap to Revenue ABIO|P/S Multiple Acasti|Market Cap to Revenue AVTE (Aerovate Therapeutics, Inc.)|Market Cap to Sales Volume VERV|P/S Multiple WINT (Windtree Therapeutics, Inc.)